The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer
NCT ID: NCT01833650
Last Updated: 2018-09-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
120 participants
INTERVENTIONAL
2013-05-31
2018-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effectiveness of a Thyme and Honey Spray for Oral Toxicities
NCT04880148
The Effect of Honey on Xerostomia and Oral Mucositis
NCT01465308
Effectiveness of Thyme Honey in Management of Xerostomia in Post Radiation Cancer Patients
NCT05859711
Salivary dysfuncTion After Radioiodine Treatment
NCT04876287
Effects for Oral Mucositis Care During Chemoradiotherapy in Cancer Patients: Evaluation of the Bee Products
NCT05625841
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard care
This arm represents the current standard care in patients with thyroid cancer undergoing radioiodine.
No interventions assigned to this group
Candy plus thymus honey mouthwash 12
This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting 12 hours after the ingestion of 131I therapy and for a duration of no more than 4 days.
thymus honey mouthwash
Candy plus thymus honey mouthwash 24
This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting 24 hours after the ingestion of 131I therapy and for a duration of no more than 4 days.
thymus honey mouthwash
Candy plus thymus honey mouthwash 1
This arm will consist 30 patients and will be the one of the intervention groups where each patient will be instructed to suck 1 or 2 lemon candies every 2-3 h in the daytime plus 4 thymus honey mouthwashes in between (at least one hour after the candy sucking) starting immediate after the ingestion of 131I therapy (about 1 hour) and for a duration of no more than 4 days
thymus honey mouthwash
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
thymus honey mouthwash
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* They had a histological diagnosis of papillary, follicular, medullary or anaplastic thyroid cancer
* They had undergone total thyroidectomy
* They were able to provide consent
Exclusion Criteria
* a history of salivary-gland disorders,
* collagen tissue disease
* diabetes mellitus,
* previous radioiodine therapy or external radiation to the head or neck
* allergy to the honey
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bank of Cyprus Oncology Centre
OTHER
Cyprus University of Technology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Andreas Charalambous
Assistant Professor of Oncology and Palliative Care
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andreas Charalambous, PhD
Role: PRINCIPAL_INVESTIGATOR
Cyprus University of Technology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bank of Cyprus Oncology
Nicosia, , Cyprus
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AC-HCS-89
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.